RPS Diagnostics
Biotechnology ResearchFlorida, United States11-50 Employees
RPS Diagnostics (RPS) is an emerging developer, manufacturer, and marketer of cost-effective point-of-care (POC) tests for systemic infectious disease and antibiotic stewardship. The company’s innovative and patented FebriDx® test is a rapid, disposable, in-office test that uses a fingerstick blood sample to help identify a clinically significant immune response and differentiate bacterial from viral causes for fever in acute respiratory infection. With a 97% negative predictive value, FebriDx delivers results in 15 minutes and can be used to help triage infectious patients during the initial office visit, providing clinicians with actionable information that can be used to limit unnecessary antibiotics. The FebriDx test is commercially available in Australia, Canada, Europe, the Gulf Cooperative Countries, Saudi Arabia, Singapore, and the United Kingdom. At this time, the FebriDx test has not received U.S. Food and Drug Administration (FDA) clearance and is not commercially available in the United States. RPS Diagnostics is a trade name of Rapid Pathogen Screening, Inc., a wholly owned subsidiary of RPS Diagnostics, Inc. For more information on RPS and its products, visit RPSdetectors.com.
1-888-653-2347 
support@leadiq.com 
